Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment

Case Reports in Oncology
19 Jan, 2019 ,

This is a case report of a 25-year-old patient treated for relapsing remitting multiple sclerosis (RRMS) with natalizumab had a rapid progression of a low grade squamous intraepithelial lesion to a FIGO stage 1B1 squamous cell carcinoma of the uterine cervix within 2 years. This case and existing evidence on increased risk of developing cervical dysplasia under natalizumab show that MS patients require close annual cervical screening.